Nav: Home

DHEA improves vaginal discomfort after menopause

January 05, 2016

CLEVELAND, Ohio (January 5, 2016)--A new phase III trial with positive results is taking intravaginal DHEA a step closer to governmental approval. The formulation could provide women who cannot or do not wish to use intravaginal estrogen with an effective vaginal alternative for easing vaginal symptoms and pain with sex after menopause. The trial results were published online today in Menopause, the journal of The North American Menopause Society.

Without hormonal treatment after menopause, vaginal tissues atrophy, the lining thins and secretes less and less fluid, and the pH becomes more alkaline, which leads to discomfort with sex as well as increased susceptibility to vaginal infections and urinary problems for many women. In fact, 84% of the women in this clinical trial had moderate to severe vaginal dryness.

But compared with the 157 women who used a placebo, the 325 women who used the daily 0.5% DHEA (6.5 mg) ovules enjoyed significant improvements after 12 weeks. Their scores on a scale of 0 to 3 for pain with sex dropped a significant 0.36 points more than for the women who used the placebo. The women who used DHEA also had significantly less thinning of the vaginal lining, showing an 8.44% greater increase in lining cells called "superficial cells" and a 27.7% greater decrease in parabasal cells, the immature precursors of the superficial cells. The DHEA users' moderate to severe vaginal dryness also improved by a significant 0.27 points more (also on a scale of 0 to 3). Gynecologists who examined the women saw 86% to 121% better improvements in vaginal secretions, integrity of the vaginal lining, lining thickness, and tissue color in the women who used DHEA, and their vaginal pH shifted 0.66 points more toward acidity.

Moisturizers and lubricants as nonhormonal alternatives to intravaginal estrogen can temporarily ease pain with sex and provide moisture, but they cannot correct the physical changes that produce the symptoms. However, DHEA (also known as dehydroepiandrosterone), a hormonal precursor of estrogens and androgens, does produce improvements.

"Although this medication is considered 'hormonal,' the mechanism appears to be primarily local with minimal side effects beyond vaginal discharge from the suppository," explains NAMS Executive Director JoAnn V. Pinkerton MD, NCMP. "DHEA is transformed into estrogens within the parabasal cells, prompting the maturation process that ultimately transforms them into superficial cells. Its action seems to be entirely within the cells, and no significant amount of sex hormone gets released into the circulation.

"That means," she added, "that intravaginal DHEA avoids the raised hormone levels that might stimulate breast tissue or the lining of the uterus, which are concerns for women at risk of estrogen sensitive cancers, or cancer recurrence, in these organs] Women who have been treated for these cancers often have severe vulvovaginal symptoms and and need safe and effective treatment options." Notably, this therapy has not been tested in patient at risk or with a history of breast cancer. And of course, the use of any type of hormonal treatment options whether it be this new DHEA suppository if it receives FDA approval or FDA approved and available low dose vaginal estrogens and systemic ospemifene (Osphena), always need to be discussed with their oncologist.

With results from nearly 500 women who participated in this prospective, randomized, double-blind, placebo-controlled trial, EndoCeutics has reached the number of study subjects the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutics for Human Use and the FDA require before this DHEA vaginal suppository or "ovule" (Prasterone) can be approved.

The article detailing the trial results, "Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause," will be published in the March 2016 print edition of Menopause.
-end-
Founded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field--including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit http://www.menopause.org.

The North American Menopause Society (NAMS)

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.